September 30, 2014 - Gallus BioPharmaceuticals, LLC has been acquired by DPx Holdings B.V., privately owned by JLL Partners and Royal DSM and the parent company of Patheon. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees. Please visit the Patheon LinkedIn page to learn more about our expanded capabilities and to follow Patheon. Visit our website at www.Patheon.com
